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Inhibitors of cAMP- and cGMP-phosphodiesterases
(PDEs) are important substances which are in clinical use
or under development for the therapy of plethora of dis-
eases, such as erectile dysfunction, heart failure and mem-
ory disorders. However, there are very few methods
available to screen new substances for their PDE inhibi-
tory activity in intact living cells. Current methods using
reporter cell lines are rather indirect and based e.g. on cal-
cium imaging of cyclic nucleotide gated channel activity
[1].
To develop a new strategy for PDE-inhibitor screening, we
used fluorescence resonance energy transfer (FRET)-based
sensors for cAMP and cGMP, which consist of a single
cAMP/cGMP-binding domain flanked by a pair of green
fluorescent protein mutants [2,3]. To directly monitor the
activity of a PDE of interest, we fused these sensors to the
N-termini of several PDEs: cAMP sensor Epac1-camps was
fused to the N-terminus of PDE4A1 or to PDE3A with
deleted N-terminal hydrophobic region 1 (amino acids 1–
279), cGMP sensor cGES-DE2 was fused to the N-termi-
nus of PDE5A1. Control experiments with such chimeric
proteins demonstrated that the fusion of PDE did not
affect the binding properties of the sensors and, con-
versely, the catalytic activity of the PDEs was not altered
by the presence of the sensors on their N-termini.
Fusion proteins transfected into HEK293a cells were uni-
formly distributed in the cytosol and reacted to the addi-
tion of subtype-specific PDE inhibitors or IBMX with a
robust decrease (Epac1-camps-PDE4A1 and Epac1-camps-
PDE3A sensors) or increase (cGES-DE2-PDE5 sensor) of
FRET, which was measured in a 96-well plate using high-
throughput iMIC microscope (Till Photonics). The IC50-
values for various PDE inhibitors measured in our system
correlated well with the published data from in vitro
assays. Epac1-camps-PDE3A sensor was also able to report
a cGMP-dependent inhibition of PDE3A-activity.
In addition to well established techniques, our assay
allows to perform a rapid and direct screening of PDE
inhibitors for various enzyme isoforms in living cells and
gives kinetic information about whether inhibitors can
enter the cell and how fast they block certain PDE.
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